46 results about "Tumor Stem Cells" patented technology

The application belongs to the field of pharmacy, and particularly relates to a whole-process targeting polypeptide molecule with the functions of targeting brain capillary endothelial cells, tumor neovascular endothelial cells, tumor pseudo vascular, tumor cells and tumor stem cells, a stable and optimized polypeptide molecule, and a modified complex and drug delivery system for tumor diagnosis and treatment. The application prepares a whole-process targeting polypeptide WVAP and a WVAP modified drug and high polymer carrier material, and applies the WVAP to the construction of a drug delivery system for tumor imaging and targeted therapy. The results show that the WVAP can cross the blood-brain barrier, target tumor neovascular and cross the blood-tumor barrier, target tumor pseudo vascular, tumor cells and tumor stem cells; and the nano drug delivery system constructed by the WVAP modified high polymer carrier material can effectively deliver the loaded drug to the brain, target tumor tissues, and significantly improve the anti-tumor efficacy.

The invention belongs to the technical field of anti-tumor drugs, and particularly relates to a flexible drug-loaded cell microparticle capable of efficiently targeting tumors and a preparation method of the flexible drug-loaded cell microparticle. Comprising tumor cell-derived drug-loaded microparticles coated with chemotherapeutic drugs, and a flexible regulator modified on the surfaces of the tumor cell-derived drug-loaded microparticles, the flexible regulator comprises a saponin compound and / or a steroid compound, and can regulate and control the hardness of the tumor cell-derived drug-loaded microparticles. The tumor cell-derived drug-loaded microparticles are modified, so that the enrichment and deep penetration of the drug-loaded microparticles in tumor tissues can be remarkably improved, and the efficient targeted delivery of the tumor tissues is realized. Meanwhile, efficient uptake of tumor stem cells to the medicine is promoted, targeted killing is achieved, the tumor stem cells are effectively removed, and tumor growth is remarkably inhibited. In addition, circulating tumor cells can be efficiently targeted, accurate delivery of tumor metastasis is achieved, and tumor metastasis is remarkably inhibited by inhibiting migration and invasion of tumor cells and reducing formation of lung metastasis.

The invention relates to the technical field of preparation of anti-cancer drugs, in particular to a temperature-sensitive hydrogel delivery drug based on an ALDH1 inhibitor and a preparation method and application of the temperature-sensitive hydrogel delivery drug. The thermo-sensitive hydrogel delivery drug is formed by compounding an ALDH1 inhibitor entrapment core, a tumor targeting modification layer and a thermo-sensitive hydrogel matrix system, and through triple technology integration, the defects that an existing delivery system is insufficient in targeting, uncontrollable in drug release and the like are overcome. The delivered drug can significantly inhibit the activity of tumor stem cells, reduce the toxicity of organs, and provide a new scheme for precise treatment of bladder cancer.

The invention discloses a bisindole compound as well as a synthesis method and anti-tumor application thereof. The molecular structure of the bisindole compound is shown in the specification. The bisindole compound XQ-010 has the remarkable effects that the bisindole compound XQ-010 can be used as an IL-6 / STAT3 signal channel regulator for tumor treatment, particularly has unique advantages in the aspect of inhibiting tumor growth and metastasis based on the inhibiting effect of the bisindole compound XQ-010 on CD133 + and CD44 + tumor stem cells, and has important clinical application value and development prospect.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

The invention belongs to the technical field of biological medicine, and discloses application of mitoxantrone liposome (LipoMIT) in preparation of a medicine for inhibiting ovarian cancer stem cells and / or improving ovarian cancer relapse and / or drug resistance. It is found for the first time that LipoMIT has a good inhibiting effect on the ovarian cancer stem cells; the medicine can be used for improving the problems of relapse and drug resistance of ovarian cancer, not only can fill the blank of the problems of drug resistance and relapse in ovarian cancer treatment, but also can fill the technical blank of LipoMIT in the field of ovarian cancer treatment in the prior art. Lipo-MIT plays a role through targeting tumor stem cells, the risk of ovarian cancer recurrence and drug resistance is reduced fundamentally, the bottleneck that only tumor cells are killed but tumor stem cells cannot be eradicated in traditional treatment is broken through, and the clinical problems of high recurrence and high drug resistance of ovarian cancer in the prior art are solved.

The invention discloses application of a PKC beta inhibitor 1 as an NID1 inhibitor, and relates to the technical field of biological medicines. The invention provides an application of a PKC [beta] inhibitor 1 as an NID1 inhibitor in preparation of antitumor drugs. By constructing a systematic screening and verification system, it is determined for the first time that the PKC beta inhibitor 1 plays a significant anti-tumor activity by efficiently blocking the interaction between NID1 and integrin alpha5beta1, and an innovative treatment strategy is provided for targeting tumor stem cells and reversing drug resistance.

The invention relates to a hypoxia targeting hyaluronic acid nano delivery system and a construction method and application thereof, the construction method comprises the following preparation method: S1, dissolving 2-nitroimidazole and K2CO3 in dimethylformamide, carrying out high temperature alkali treatment, adding N-Boc-bromoethylamine, and carrying out high temperature reaction to obtain Boc-NIH; s2, dissolving the Boc-2-NIH in dichloromethane, adding trifluoroacetic acid for deprotection, and adjusting the pH value to be neutral, so as to obtain 2-NIH; s3, dissolving HA in deionized water, sequentially adding EDC and NHS to activate carboxyl, then adding 2-NIH, reacting at room temperature, and dialyzing to obtain a hypoxic targeting hyaluronic acid nano delivery carrier HA-NIH; s4, HA-NIH loads a drug, and the hypoxia targeted hyaluronic acid nano delivery system is formed. According to the invention, a bifunctional nano system with CD44 active targeting and hypoxia response release is successfully constructed, a dynamic regulation and control mechanism of HA molecular weight on a targeting-permeation-retention effect is provided, and a synergistic effect of tumor stem cell microenvironment specific response and drug space-time release is realized.

The application discloses a ROS / GSH responsive hyperbranched zwitterionic micelle and a preparation method and application thereof, and relates to a drug delivery system, ROS responsive zwitterionic micelles and GSH responsive zwitterionic micelles are prepared respectively, the ROS responsive zwitterionic micelles are loaded with anti-angiogenic drugs, and the GSH responsive zwitterionic micelles are loaded with anti-tumor stem cell drugs, so that the combined treatment of blood vessel normalization and tumor stem cell killing is realized, while the blood vessel normalization is realized, the restriction of the small intercellular gap of vascular endothelial cells caused by the blood vessel normalization on the enrichment and penetration of subsequent nano drugs in tumor sites is effectively solved, and the change of the interstitial pressure of tumor tissue caused by the blood vessel normalization is fully utilized to promote the deep penetration of small-size GSH responsive zwitterionic micelles into the internal region of the tumor, so that the killing of tumor stem cells is completed, and the combined treatment of the blood vessel normalization therapy and the tumor stem cell therapy is effectively realized.

The invention relates to the technical field of nano-drugs, in particular to a nano-drug for treating triple negative breast cancer as well as a preparation method and application of the nano-drug. The nano-drug takes hyaluronic acid modified hollow mesoporous copper zinc sulfide nanoparticles as a carrier, and cholesterol oxidase is loaded in the nano-drug. The preparation method adopts a one-pot wet chemical method, and a carrier with a regular structure is formed based on a Kirkendall effect. The nano-drug disclosed by the invention can be delivered to a tumor site in a targeted manner, is rapidly degraded in a weak acid microenvironment, synchronously releases cholesterol oxidase, metal ions with Fenton-like activity and H2S gas, and synergistically sensibilizes ferroptosis and efficiently eradicates tumor stem cells by triggering a cascade reaction of cholesterol depletion-lipid raft destruction-lipid peroxidation storm; a brand new treatment scheme is provided for solving the problems of drug resistance and relapse of the triple negative breast cancer.

The invention discloses an FGF2 inhibitor composition of a targeted iCAFs subgroup and application of the FGF2 inhibitor composition in bladder cancer prevention and treatment, and relates to the technical field of FGF2 inhibitor compositions of targeted iCAFs subgroups, the FGF2 inhibitor composition is used for preparing a medicine for bladder cancer prevention and treatment, the composition comprises an FGF2 inhibitor, and the FGF2 inhibitor can inhibit the bladder cancer by inhibiting interaction between FGF2 secreted by ICAM1 + iCAFs and tumor stem cell surface CD44, so that the bladder cancer can be prevented and treated, and the bladder cancer can be prevented and treated. According to the application disclosed by the invention, ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation in a bladder cancer recurrence related tumor microenvironment is targeted, a fibroblast growth factor FGF2 signal secreted by the ICAM1 + inflammatory cancer related fibroblast iCAFs subpopulation is specifically inhibited, the dependency support of the tumor microenvironment on the stemness maintenance of the tumor stem cells is destroyed, and the stemness maintenance of the recurrence related tumor stem cell subpopulation is inhibited. Therefore, the biological basis of tumor recurrence and progression is weakened from the source.

The invention provides an mRNA (messenger Ribonucleic Acid) medicine for inhibiting tumor stem cells and reducing the dryness of the tumor cells and a preparation method of the mRNA medicine. The mRNA medicine comprises any one or a combination of at least two of linear PTEN mRNA, self-replicating PTEN mRNA and annular PTEN mRNA; the linear PTEN mRNA comprises a 5 'UTR (Untranslated Region) sequence, a PTEN protein coding sequence and a 3' UTR sequence; the nucleotide sequence of the PTEN protein coding sequence comprises a sequence as shown in SEQ ID NO. 1. The mRNA nano-drug prepared by the invention not only has high transfection efficiency in tumor stem cells, but also can induce differentiation of the tumor stem cells and remarkably inhibit growth of the tumor stem cells; in drug-resistant tumor cells, the stemness of the drug-resistant tumor cells is inhibited, so that the sensitivity to chemotherapy, targeted antibodies, immunotherapy and the like is improved, and the killing effect of the drug is improved. The invention also shows an excellent anti-tumor effect in a human tumor cell line xenotransplantation model of the drug-resistant breast cancer in vivo, and provides a promising treatment strategy for the treatment of the drug-resistant breast cancer.

The application discloses a tumor stem cell inhibiting medicine based on gene regulation and a preparation method thereof, and belongs to the technical field of biological medicines. The medicine takes a targeted interference fragment of a tumor stem cell specific regulation gene TSC-G as a core active component, and is composed of only the targeted interference fragment and a modified liposome. The modified liposome is composed of DSPC, Chol and PEG-DSPE in a specific ratio, and has high targeting property and good stability. The preparation method comprises four steps of targeted interference fragment synthesis, modified liposome preparation, medicine assembly and purification, and has simple process and high purity. The medicine can effectively inhibit self-renewal, proliferation and differentiation of tumor stem cells, the tumor stem cell inhibition rate is greater than or equal to 88%, the tumor volume inhibition rate in vivo is greater than or equal to 78%, the medicine has no toxicity to normal body cells, the technical scheme is unique, the medicine can be used for clinical tumor treatment, and the problem of tumor recurrence and drug resistance can be solved from the root.

An apparatus for rapid screening of tumor stem cells and a method. The apparatus comprises a microscope slide (1) and a cover slip (2) for use under a microscope; the microscope slide (1) is located at the bottom and the cover slip (2) is located at the top; the microscope slide (1) and the cover slip (2) are sealed around their periphery and form an included angle of 2-10 degrees therebetween, the distance between front ends is 200-300 microns, the distance between rear ends is 100-150 microns, a liquid inlet tube (4) and a cleaning tube (5) are provided at the front ends, and a liquid outlet tube (6) is provided at the rear ends; the liquid inlet tube (4) is connected to a blood test vial (7), the cleaning tube (5) is connected to a cleaning vial or a reagent vial (8), and the liquid outlet tube (6) is connected to a blood collection vial (9); the microscope slide (1) is provided with one or more U-shaped grooves (11), the depth of the U-shaped groove (11) is 100-500 microns, and the width of the U-shaped groove (11) is 100-300 microns.

This invention discloses an anti-tumor stem cell preparation and its preparation method, belonging to the field of biomedical technology. The stem cell genome contains an introduced target gene, a hypoxia-responsive element, and a regulatory element. The target gene is linked downstream of the regulatory element and expressed under its regulation. The regulatory element is located downstream of the hypoxia-responsive element. The preparation process of the anti-tumor stem cell preparation includes the following steps: S1, plasmid construction; S2, lentiviral packaging; S3, stem cell culture; S4, cell transfection; S5, cell screening. This invention uses the NTRK1 promoter and VEGFA-1 enhancer to synergistically regulate the highly efficient and specific expression of the NADH oxidase gene in the adrenocortical tumor environment, catalyzing the generation of a large amount of reactive oxygen species to induce cancer cell apoptosis. This invention solves the problem in existing technologies where stem cell-targeted gene therapy relies solely on the homing effect of stem cells, resulting in a lack of specific targeting ability to the lesion site.

The invention belongs to the technical field of biological medicine, discloses a double phenotype hepatocellular carcinoma diagnostic kit and application thereof, and integrates and analyzes DPHCC stem cell heterogeneity through a single-cell multi-omics technology. The characteristics of tumor stem cells (CSCs) of DPHCC are analyzed from a proteome and transcriptome two-dimensional system on the single cell level. And the influence of Non-DPHCC tumor cells in a DPHCC sample is avoided. The correlation between the SPINT2 and the CK19 and the DPHCC is determined, and the SPINT2 is poorly related to the prognosis of the DPHCC. The discovery provides a new target spot for targeting CSCs.

The application belongs to the technical field of biology and specifically relates to application of fibrinogen alpha chain in chimeric antigen receptor T cell (CAR-T) therapeutic drugs, wherein the fibrinogen alpha chain plays a direct role in maintaining tumor cell population stemness by activating a TLR4-NF-kappa B signal pathway. Meanwhile, the fibrinogen alpha chain promotes a significant increase in expression level and proportion of TROP2 in triple-negative breast cancer (TNBC) by activating the TLR4-NF-kappa B signal pathway, and shows enhanced sensitivity to targeted TROP2-CAR-T therapy. Therefore, through exogenous regulation of the fibrinogen alpha chain, up-regulation of tumor cell TROP2 expression and homogenization among tumor cell subpopulations are induced, thereby providing an important scheme for tumor stem cell targeted therapy of TNBC.

This invention belongs to the field of biomedical technology and relates to the application of a diagnostic kit for early gastric adenocarcinoma using gastric tumor stem cells that highly express PDZK1IP1 based on cellular characteristics and spatial transcriptional features. This invention is the first to propose a novel diagnostic method for early gastric adenocarcinoma using gastric tumor stem cells that highly express PDZK1IP1 based on cellular characteristics and spatial transcriptional features. It also clarifies for the first time the functional phenotype and biological significance of PDZK1IP1 in gastric adenocarcinoma cells. The results of this invention show that inhibiting PDZK1IP1 can weaken the proliferation and tumor spheroid formation abilities of gastric cancer cells, and further inhibit the growth rate and size of subcutaneous tumors in mice, suggesting that PDZK1IP1 could serve as a new target for gastric cancer treatment, providing a new strategy for the clinical treatment of gastric adenocarcinoma.

The application discloses a kind of serum-free medium for efficiently enriching tumor stem cells and application thereof, belong to the technical field of cell biology.The serum-free medium includes basic medium, basic additive factor, functional additive component;Among them, functional additive component includes: 1 μM-1mM of alpha-ketoglutaric acid dimethyl ester, 10nM-10 μM of butyl benzyl phthalate, 0.01 μM-1 μM of endothelin-1, 0.01mM-1mM of uridine diphosphate glucose, 1nM-100nM of tetrabromobisphenol A.The application provides stable stemness maintenance conditions for tumor stem cells by adding functional additive component to serum-free medium;At the same time, the synergistic effect between functional additive component and other components significantly improves the enrichment efficiency of tumor stem cells, and has the advantage of low cost;Therefore, it has good application prospect in efficient enrichment of tumor stem cells.

The application discloses a kind of bionic fish ladder microfluidic chip and integrated cell sorting and drug screening platform thereof.The fish ladder microfluidic chip adopts fish ladder-shaped main channel of tapering-dilating alternation, internally set micro barrier array with gap gradually decreasing, and vortex stop zone is formed in dilating section, overall imitates the ladder-ramp pool structure of "fish ladder" in fish migration channel.Based on cell deformation difference, it realizes label-free, mild, high-throughput sorting;After sorting, cell directly flows into downstream 3D culture chamber, can in situ carry out drug screening.The application integrates sorting, screening and culture in single chip, avoids damage and state change caused by cell transfer in traditional method.The "fish ladder microfluidic" concept defined in the application has clear bionic source and identifiable structural characteristics, and can be used as an iconic term in the technical field.Especially suitable for efficient screening of active ingredients in complex system of traditional Chinese medicine and tumor stem cell research.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The invention discloses a biomarker for predicting drug resistance of pancreatic cancer to a KRAS inhibitor and application of the biomarker, and relates to the technical field of biological medicines. The invention reveals that the immune checkpoint molecule VTCN1 mediates the drug resistance of the KRAS inhibitor by activating the TNF-NF-kappa B pathway for the first time, breaks through the limitation that the existing drug resistance mechanism only focuses on gene mutation or bypass activation, and provides a brand new target for drug resistance intervention; tumor stem cell characteristics and TNF pathway activation are synchronously inhibited, and the defect that an existing single-pathway inhibitor is insufficient in curative effect is overcome. Meanwhile, the VTCN1 inhibitor and the KRAS inhibitor are combined for use, the drug resistance of the pancreatic cancer to the KRAS inhibitor can be effectively reversed, so that the treatment effect of the KRAS inhibitor is further improved, the drug resistance of cancer cells to the KRAS inhibitor is reduced, and an application prospect is provided for precise treatment of the pancreatic cancer.

The application belongs to the technical field of medicine, and particularly relates to a nano-carrier for targeting anti-tumor cells and tumor stem cells, and a preparation method and application thereof. The application provides an amphiphilic block copolymer, which is formed by connecting polycurcumin with a double sulfur bond and hyaluronic acid through an amide bond to form an amphiphilic block copolymer. The amphiphilic block copolymer has a higher curcumin loading capacity, and the content of curcumin can reach 25%. Meanwhile, the presence of the amide bond makes it more stable in a physiological environment when used as a carrier, and can reduce the shedding of the target head before reaching the tumor target. The amphiphilic block copolymer of the application can load chemotherapeutic drugs, can simultaneously target breast cancer cells and breast cancer stem cells, and can target breast cancer cells and breast cancer stem cells at the cell level and in the animal body after loading the drugs, and can play an anti-breast cancer effect, and can be used as a new nano-carrier for anti-tumor, and provides a new choice for anti-tumor treatment.

The application provides a supercritical CO2 assisted preparation of quercetin nanoparticles and application thereof to resisting gastric cancer stem cells. The nanoparticles are prepared by encapsulating quercetin with polylactic acid-co-ethylene glycol (PLGA), so as to solve the problems of poor water solubility and low bioavailability of quercetin and improve the inhibiting effect of quercetin on gastric tumor stem cells. Through a specific preparation process, quercetin-PLGA nanoparticles (Qu-PLGA NS) with uniform particle size and uniform dispersion are obtained. Experimental results show that the Qu-PLGA NS can effectively inhibit the growth and proliferation of gastric tumor stem cells, induce apoptosis of the gastric tumor stem cells, and significantly reduce the invasion and metastasis ability of the gastric tumor stem cells. In addition, the nanoparticles can also reverse the multi-drug resistance of the gastric tumor stem cells, improve the curative effect of a chemotherapeutic drug, and reduce side effects. The application provides a new idea and method for the treatment of gastric cancer and has important clinical application value.

The invention discloses a pharmaceutical composition for inhibiting expression of leukemia tumor stem cell markers and application of the pharmaceutical composition, and relates to the technical field of leukocyte tumor cell inhibition. The active ingredients of the pharmaceutical composition are oleanolic acid and illlisemom. The invention reveals that oleanolic acid inhibits expression of key markers Sox9, Nanog, CD133 and CD44 of leukemia tumor stem cells by targeting FDX1 / DLAT axis for the first time, and further inhibits drug resistance and recurrence of malignant tumors. When the compound is used in combination with a copper ion carrier ilismor, a relatively large synergistic effect can be generated by inhibiting the expression of tumor stem cell markers Sox9, Nanog, CD133 and CD44, and the stemness of leukemia is remarkably inhibited. The composition provides a new drug development strategy with a clear mechanism for treatment of leukemia.

The application discloses application of EPHX2 in preparation of products or medicines for diagnosing and treating glioblastoma, and belongs to the field of biological medicine. The application of a reagent for detecting the expression level of EPHX2 in preparation of products for diagnosing glioblastoma, by detecting the mRNA or protein expression level of EPHX2 in a sample from a subject, when the mRNA or protein expression level of EPHX2 in the sample is low, it indicates that the prognosis of glioblastoma is good; when the mRNA or protein expression level of EPHX2 in the sample is high, it indicates that the prognosis of glioblastoma is poor; the application of a substance for inhibiting the hydrolytic enzyme activity of EPHX2 in preparation of medicines for treating glioblastoma and cachexia, which can simultaneously play a dual role of killing tumor stem cells and relieving muscle atrophy and neurological symptoms, and provides a safe and effective combined treatment scheme for glioblastoma.

This invention discloses a reagent for inhibiting Acetyl-CoA or GCN5 acetyltransferase and its application, belonging to the field of biomedical technology; a drug comprising a reagent capable of inhibiting Acetyl-CoA synthesis or GCN5 inhibition; tumor stem cells interact with T cells, and T cells can obtain a large amount of Acetyl-CoA from tumor stem cells; Acetyl-CoA, as an acetylation substrate, can acetylate Blimp-1 under the action of GCN5 acetyltransferase, downregulating Blimp-1 expression, thereby inhibiting TRM cell differentiation; by targeting and inhibiting Acetyl-CoA synthesis and GCN5 inhibition, Blimp-1 expression is upregulated, TRM cell differentiation is maintained, and the body's anti-tumor ability is improved; the Acetyl-CoA and GCN5 provided by this invention provide new targets for the treatment of NSCLC.

The present application relates to the technical field of antitumor drugs, and particularly relates to a kind of PROTACs compound targeted to degrade BCL6 and application thereof, and the compound is the compound shown in formula (I) or its stereoisomer, geometric isomer, tautomer, nitroxide, solvate, pharmaceutically acceptable salt, metabolite or prodrug.The PROTACs compound targeted to degrade BCL6 provided in the present application connects BCL6 protein ligand and E3 ubiquitin ligase ligand through chemical groups;The compound can be used to inhibit the proliferation, growth, migration, infiltration, clonal formation and metastasis of tumor cells, promote the apoptosis of cancer cells, promote the autophagy of tumor cells, overcome the drug resistance of chemotherapy or targeted therapy of tumor, inhibit the growth of tumor stem cells, and prolong the survival period of tumor patients.

The present application belongs to the technical field of biological medicine, and relates to the use of a combination of a BMI1 inhibitor and a Myc inhibitor for treating cancer. After the BMI1 inhibitor and the Myc inhibitor are combined for treating cancer, especially head and neck squamous cell carcinoma (HNSCC), the present application can effectively and continuously eliminate tumor stem cells, thereby inhibiting tumor growth, treating cancer, and preventing tumor recurrence.

The invention discloses a healthy individual-derived autologous tumor stem cell line establishment method, which is characterized by comprising the following two stages: a first stage, inducing healthy human-derived somatic cells into hiPSC; in the second stage, the hiPSC is induced to be converted into the tumor stem cells, specifically, firstly, a tumor-derived conditioned culture medium is prepared, then under the synergistic effect of the tumor-derived conditioned culture medium and an induction adjuvant, the hiPSC is induced to be converted into the tumor stem cells, and the healthy individual-derived tumor stem cells are obtained after culture. According to the invention, the somatic cell-derived iPSC of healthy people can be induced into tumor stem cells, and the method can be well applied to cancer prevention, drug screening and health management.